How to Get NAD+: Ranked by What You Cannot Inspect

How to get NAD+ has four honest answers, and the standard way of ranking them is by friction: how many steps, how long, how much of a gatekeeper stands in the way. Ranked that way, a walk in infusion wins. Ranked by how much of the analytical record you are permitted to see, it comes close to last.

This article runs both rankings, because the gap between them is the useful information. Every route below delivers the same coenzyme in the end. What differs is who holds the certificate, whether anyone in the chain checked the material for the contaminant that has actually caused harm here, and whether you are in a position to ask.

Where a route ends in a purchase, the vendor we can document precisely is disclosed below, including the question its published material does not answer.

How to get NAD+: four routes, two rankings

Friction rank is the order most readers expect. Inspection rank is the order that reflects how much of the material record you can put your hands on.

Route 1: the clinic, where the friction is lowest and so is the visibility

NAD+ has a retail clinical channel that research peptides simply do not have. Infusions are advertised on high streets, booked like a haircut and administered by staff. For anyone searching how to get NAD IV rather than a vial, this is the whole answer, and the barrier is a calendar slot rather than a gatekeeper.

What you cannot see is where the bag came from. The clinic is the pharmacy’s customer; you are the clinic’s. That places two links between you and the material record, and the default service design does not surface any of it. FDA’s compounding notice, current as of 30 October 2024, describes exactly what can go wrong along that chain: compounders using food grade nicotinamide adenine dinucleotide sold by repackagers to make intravenous products, ingredients identified as food grade not being suitable for compounding sterile drugs without appropriate processing due to the high risk of contamination with microbes and endotoxins, and adverse event reports of severe chills, shaking, vomiting and fatigue with some requiring medical treatment, which the agency describes as consistent with excessive levels of endotoxins.

None of that means clinics are uniformly careless. It means the failure has occurred in this channel, it is invisible from the chair, and the only recovery available to a customer is to ask before the line goes in: which pharmacy, what grade, and is there an endotoxin result. A clinic that can answer all three has done something most of the market has not. What these sessions cost relative to material is covered in our clinic pricing guide.

Route 2: prescription and compounding, the highest friction and the firmest paperwork

This is the route with the most steps and the strongest documentary requirements attached to it. It also surprises people, because a common claim online is that NAD+ cannot be compounded at all. On FDA’s 503A list of nominated bulk drug substances, updated 14 May 2026, Nicotinamide Adenine Dinucleotide (NAD) appears in category 1, bulk drug substances under evaluation, alongside the reduced form listed as Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH).

Category 1 means the agency does not intend to take action against a compounder for compounding drugs using substances on that list, provided the conditions in the guidance document are met. It is an interim enforcement posture during evaluation. It is not approval, the list is explicitly under evaluation, and a substance can be removed from it. Anyone quoting category 1 as a safety endorsement has inverted its meaning.

Two details matter for a reader weighing this route. First, section 503A requires that bulk drug substances used in compounding be accompanied by a valid certificate of analysis and be manufactured by an establishment registered with FDA under section 510, which is a documentary floor no other route imposes. Second, a separate entry named Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate sits in category 3, nominated without adequate supporting information, and category 3 substances are not eligible for the category 1 policy. The two names look interchangeable and are not. The full regulatory reading is in our explainer on NAD+ without a prescription.

Route 3: the research vial, where the document ends up in your hands

Research suppliers sell NAD+ in gram quantities to anyone who places an order and accepts the research use terms. Friction is low and the transaction is ordinary ecommerce. What distinguishes it analytically is custody of the record: the vial arrives with a lot number, and if the supplier publishes batch certificates you can match one to the other yourself. No other route lets you do that.

The limit of the route is the scope of the panel. Certificates in this market default to identity and purity, because that is what the rest of a peptide catalogue needs, and bacterial endotoxin testing is an addition rather than an inclusion. For NAD+, that addition is the whole point. The vendor disclosed above publishes certificates from two independent laboratories per lot as a catalogue wide practice and prices the 1,000 mg presentation at $104.00, halved to $52.00 with the code PEPTIDEDECK, which is $5.20 per 100 mg. What we cannot verify from outside is whether the NAD+ certificate carries an endotoxin line, so we treat that as an open question rather than a pass. Our purchase checklist gives the wording that gets a straight answer.

Research use labelling deserves one clarification, because buyers routinely read it as either a loophole or a guarantee and it is neither. It states an intended use. It carries no analytical warranty, it does not certify sterility, and it does not make a product suitable for anything a regulator has assessed. Our primer on what research compounds are sets out the general position, with the caveat that NAD+ is a coenzyme rather than a peptide and the identity questions differ.

Route 4: oral precursors, which answer a different question

Nicotinamide mononucleotide and nicotinamide riboside are sold widely as oral supplements and are frequently returned by searches for where to get NAD+. They are precursors that cells convert along the salvage pathway rather than NAD+ itself, and they are a different format with a different regulatory history. We do not state their regulatory status here because it was not verified for this article, and treating them as a milder version of the same purchase is the error to avoid.

What the clinical record supports, graded honestly

Every route above is downstream of the same question, which is what infused NAD+ actually does in a human being. The settled part is cellular: NAD+ is a redox cofactor consumed and regenerated continuously, and it is a substrate for enzyme families whose activity depends on its availability. That is textbook material with a deep literature.

The unsettled part is everything a clinic advertises. A 2019 pilot study in Frontiers in Aging Neuroscience was described by its authors as the first to document the fate of directly infused NAD+ in a human cohort, and it reported that plasma NAD+ and its measured metabolites did not shift until after two hours, a profile the authors read as rapid enzymatic removal from circulation. Registered clinical work on injectable NAD+ exists but is early and narrow: one example is a phase 1 study of an injectable preparation registered under the older name Coenzyme I, with an estimated twelve participants, aimed at haematopoietic recovery after cord blood transplantation rather than at any wellness indication.

Neither of those is a reason to buy or not to buy. They are a calibration: the evidence base under the entire retail market is smaller than the marketing volume suggests, and no route in this article obtains a product that a regulator has assessed.

Where most readers actually land

The prescription route has the best paperwork and the most friction, and for a great many readers it is not available in practice, because it requires a clinician willing to prescribe a compounded preparation of a substance under evaluation. The clinic route is available almost everywhere and asks nothing except money, which is exactly why it hides the most. The research vial sits in between on friction and above both on inspectability, which is why it is where most of this traffic ends up.

If that is where you are heading, the next questions are which channel to buy in and how to read what you are sent. Our channel comparison takes the first, our listing anatomy guide takes the second, and our transaction walkthrough covers what should arrive and what to do if the documents do not match the vial.